Welcome to our dedicated page for Cerevel Therapeutics Hldng news (Ticker: CERE), a resource for investors and traders seeking the latest updates and insights on Cerevel Therapeutics Hldng stock.
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) is a clinical-stage biopharmaceutical leader pioneering neuroscience therapies for central nervous system disorders. This page serves as the definitive source for official company announcements, research milestones, and financial updates.
Investors and industry observers will find curated press releases covering clinical trial progress, regulatory developments, strategic partnerships, and quarterly results. Our aggregation ensures timely access to material information about CERE's neuropharmacology pipeline targeting Parkinson's, Alzheimer's, and schizophrenia.
All content is verified at source to maintain compliance with financial disclosure standards. Bookmark this page for streamlined tracking of Cerevel's advancements in receptor-specific therapies and neuroscience innovation.
Cerevel Therapeutics (CERE) announced significant developments in its clinical pipeline and financial results for 2022. The company is currently enrolling participants in a Phase 1 trial for emraclidine targeted at Alzheimer’s disease psychosis, while its Phase 2 trials for schizophrenia are on track for data release in 1H 2024. As of December 31, 2022, Cerevel reported cash and equivalents of $950 million, projected to fund operations through 2025. Research and development expenses rose to $280.3 million, driven by ongoing clinical programs. Additionally, President Abraham Ceesay will depart on March 9, 2023.
Cerevel Therapeutics (Nasdaq: CERE) announced it will report its fourth quarter and full year 2022 financial results on February 22, 2023, prior to U.S. market open. A conference call will follow at 8:00 a.m. ET that same day. Investors can register for the call to receive dial-in details and access a live webcast on the company's website. Cerevel focuses on treating neuroscience diseases with a diversified pipeline of five clinical-stage therapies addressing conditions like Parkinson’s and epilepsy. The company emphasizes a targeted neurocircuitry approach and is engaged in ongoing R&D and potential collaborations.
Cerevel Therapeutics (Nasdaq: CERE) has announced the initiation of a Phase 1 trial for emraclidine, aimed at treating Alzheimer’s disease psychosis. Additionally, a Phase 2 trial for darigabat, targeting panic disorder, is set to begin in Q2 2023. The company is focused on expanding its neuroscience drug pipeline, addressing conditions like schizophrenia, epilepsy, and Parkinson's disease. Upcoming data readouts and a cash runway extending into 2025 position Cerevel to advance its novel therapies. A presentation at the J.P. Morgan Healthcare Conference is scheduled for January 10, 2023.
Cerevel Therapeutics (Nasdaq: CERE) has announced that CEO Tony Coles, M.D., will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023. The presentation is scheduled for 8:15 a.m. PST/11:15 a.m. EST, followed by a Q&A session with the executive team. Investors can access the live webcast on the company’s investor relations page, with a replay available later. Cerevel focuses on neuroscience diseases, with a diverse pipeline of investigational therapies targeting conditions like Parkinson’s, epilepsy, schizophrenia, and dementia-related apathy.
Cerevel Therapeutics announced positive results from a Phase 1 trial of emraclidine, a treatment for schizophrenia, indicating no significant increase in blood pressure. At week eight, the mean change in 24-hour ambulatory systolic blood pressure was -2.7 mmHg for the 10 mg dose and -0.4 mmHg for the 30 mg dose. The study confirmed that emraclidine does not cause a blood pressure increase exceeding 3 mmHg, aligning with FDA guidelines. The drug was well-tolerated, with a side effect profile consistent with earlier trials. A comprehensive Phase 2 program is set to read out in early 2024.
Cerevel Therapeutics announced promising results from its Phase 1b clinical trial of emraclidine, a selective muscarinic M4 receptor positive allosteric modulator aimed at treating schizophrenia. Findings showed statistically significant improvements in symptom severity after six weeks compared to placebo, with no major gastrointestinal side effects. The company is moving forward with its Phase 2 development program involving additional clinical trials expected to report in the first half of 2024, highlighting a potential breakthrough in schizophrenia treatment.
Cerevel Therapeutics (Nasdaq: CERE) announced participation in three key investor conferences focused on neuroscience. The events include the Guggenheim Healthcare Talks on November 15, Stifel 2022 Healthcare Conference on November 16, and the Evercore ISI HealthCONx Conference on November 29. Key executives, including Chief Medical Officer Raymond Sanchez and CEO Tony Coles, will lead engaging discussions. Live webcasts will be accessible via their investor relations webpage, with replays available post-event. Cerevel aims to advance treatments for neuroscience diseases.
Cerevel Therapeutics (CERE) has successfully completed a $599 million dual convertible debt and equity financing to enhance its neuroscience therapeutics pipeline. The company initiated the EMPOWER-3 trial for emraclidine in schizophrenia and received FDA Fast Track designation for the same drug in Alzheimer’s disease psychosis, with a Phase 1 trial expected by year-end 2022. As of September 30, 2022, Cerevel holds $1,030 million in cash and equivalents, expected to support operations into 2025.
Cerevel Therapeutics (Nasdaq: CERE) will announce its third quarter 2022 financial results on November 8, 2022, prior to the market opening. Management will host a conference call on the same day at 8:00 a.m. ET to discuss these results and recent business developments. Investors can register for the call through a provided link for dial-in information. Cerevel is focused on neuroscience diseases, boasting a pipeline with five clinical-stage therapies aimed at conditions such as Parkinson’s and schizophrenia.
Cerevel Therapeutics (Nasdaq: CERE) announced its participation in the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022. CEO Tony Coles will take part in a fireside chat at 9:20 AM ET. Investors can access the live webcast via the company's website, with a replay available afterward. Cerevel, based in Cambridge, specializes in neuroscience diseases and has a diversified pipeline, including five clinical-stage therapies for conditions such as Parkinson’s and schizophrenia.
FAQ
What is the current stock price of Cerevel Therapeutics Hldng (CERE)?
What is the market cap of Cerevel Therapeutics Hldng (CERE)?
